Glucagon-like peptide-1 receptor agonists: new strategies and therapeutic targets to treat atherosclerotic cardiovascular disease
Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of cardiovascular mortality and is increasingly prevalent in our population. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) can safely and effectively lower glucose levels while concurrently managing the full spectrum of ASCVD r...
Saved in:
Main Authors: | Tianyu Wang (Author), Juncan Ding (Author), Xinyi Cheng (Author), Qiang Yang (Author), Pengfei Hu (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2024-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease
by: Laurie L. Baggio, et al.
Published: (2021) -
Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
by: Seungah Lee, et al.
Published: (2017) -
The Therapeutic Potential of Glucagon-like Peptide 1 Receptor Agonists in Traumatic Brain Injury
by: Anja Harej Hrkać, et al.
Published: (2024) -
Pharmacoeconomic characteristics of agonists of receptors for glucagon-like peptide-1 and medicines on their base
by: I. N. Dyakov, et al.
Published: (2021) -
Glucagon-like peptide-1 receptor agonists and derivatives in the treatment of obesity - review
by: Michal Rabenda, et al.
Published: (2024)